Viewing Study NCT00570258

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:08 AM
Ignite Modification Date: 2026-02-21 @ 11:18 PM
Study NCT ID: NCT00570258
Status: TERMINATED
Last Update Posted: 2021-03-30
First Post: 2007-12-06
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Sponsor: University of Arkansas
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Breast Cancer View
Keywords: